ASBPW · Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc. (ASBP) reported Q1 FY2026 results reflecting early commercial traction in nutraceuticals alongside ongoing biopharma investments. Revenue reached $28.4K, derived entirely from customer orders evidenced by issued invoices, which constitute the Company's contracts with customers. This generated gross profit of $5.8K and a gross margin of 20.3%, demonstrating initial pricing power in the nutraceutical segment as the Company builds its biopharma pipeline.

Operating income stood at -$1.6M, driven by expenses that the Chief Executive Officer—as the Company's Chief Operating Decision Maker (CODM)—closely monitors alongside cash and cash equivalents for resource allocation and performance evaluation. Gross margin, operating expenses including general and administrative, research and development, and sales and marketing costs are reviewed by the CODM to manage and forecast cash needs, ensuring sufficient capital for operations. The resulting operating margin of -5806.0% underscores the capital-intensive nature of biopharma development at this early stage.

Net income was -$3.2M, a 79.8% improvement from -$15.9M in Q1 FY2025, with diluted EPS at -$20.57 versus -$0.42 YoY. This narrowing reflects the period-to-period dynamics where the net loss was partially offset by changes in working capital, including increases in prepaid and other current assets, inventories, and decreases in accounts payable and accrued expenses. Other expenses, net, and income tax expense further factor into CODM oversight to sustain liquidity.